Tumor Infiltrating Lymphocytes But Not Serum Pituitary Antibodies Are Associated with Poor Clinical Outcome after Surgery in Patients with Pituitary Adenoma
Open Access
- 1 January 2010
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 95 (1) , 289-296
Abstract
Context: Serum pituitary antibodies (Pit Abs) and tumor-infiltrating lymphocytes (TILs) have been described in pituitary adenomas, but their clinical significance remains unknown. Objective: The objective of the study was to assess Pit Abs and TILs prevalence in pituitary adenomas and their influence on clinical outcome. Design: This was a prevalence case-control study. Patients and Setting: Two hundred ninety-one pituitary adenoma cases (110 non-secreting, 30 ACTH-69 GH-71 prolactin- and 13 TSH-secreting adenoma; 177 operated and 114 untreated), 409 healthy controls, and 14 autoimmune hypophysitis were enrolled in a tertiary referral center. Intervention: Pit Abs were measured using immunofluorescence in all cases and controls (n = 714). The presence of TILs was evaluated using CD45 staining in a subset of adenomas surgically treated (n = 72). Main Outcome Measure: Clinical response of pituitary adenoma after surgery was evaluated. Results: Pit Abs prevalence was higher in adenomas (5.1%) than healthy subjects (0.7%, P < 0.0001) and lower than in autoimmune hypophysitis patients (57%, P < 0.0001). Similarly, TILs prevalence was higher in adenomas than normal pituitary (P = 0.01) and lower than in autoimmune hypophysitis (P < 0.0001). No correlation between Pit Abs and TILs was found (P = 0.78). A poor clinical outcome was more common in adenoma patients with TILs (11 of 18, 61%) than in those without (17 of 54, 31%, P = 0.026). Multivariate regression analysis identified the presence of TILs as independent prognostic factor for persistence/recurrence of pituitary adenoma. Conclusions: TILs and Pit Abs are present in a significant number of pituitary adenoma patients. Cell-mediated immunity appears to be predictive of a less favorable clinical outcome.Keywords
This publication has 42 references indexed in Scilit:
- Immunoproteomics to identify tumor-associated antigens eliciting humoral responseCancer Letters, 2009
- Pituitary and systemic autoimmunity in a case of intrasellar germinomaPituitary, 2009
- Adenoma-infiltrating Lymphocytes (AILs) are a Potential Marker of Hereditary Nonpolyposis Colorectal CancerAmerican Journal of Surgical Pathology, 2008
- Novel autoantigens in autoimmune hypophysitisClinical Endocrinology, 2008
- The impact of T‐cell immunity on ovarian cancer outcomesImmunological Reviews, 2008
- Autoantibodies to tumor‐associated antigens: reporters from the immune systemImmunological Reviews, 2008
- Rathke’s cleft cyst rupture as potential initial event of a secondary perifocal lymphocytic hypophysitis: proposal of an unusual pathogenetic event and review of the literatureNeurosurgical Review, 2008
- Lymphocytic Hypophysitis Occurring Simultaneously with a Functioning Pituitary AdenomaEndocrine Journal, 2008
- Concurrent lymphocytic hypophysitis and pituitary adenomaJournal of Neurosurgery, 2006
- Prevalence of Lymphocytic Infiltrate in 1400 Pituitary Adenomas.Endocrine Journal, 1998